MedTrace Logo

Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma

NCT02399124 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-01-06

No results posted yet for this study

Summary

This experiment is designed for post marketing data collection of a cryosurgical system \[PROSENSE™ of IceCure Medical\], for the treatment of renal cell carcinoma (RCC).

Conditions

Interventions

DEVICE

PROSENSE™

single arm, open label, PROSENSE™ treatment

Sponsors & Collaborators

  • Bnai Zion Medical Center

    collaborator OTHER_GOV

  • Assaf-Harofeh Medical Center

    collaborator OTHER_GOV

  • IceCure Medical Ltd.

    lead INDUSTRY

Principal Investigators

  • Halachmi Sarel, Prof. · Bnei Zion Medical Center, Israel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2026-02-28
Completion
2026-03-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02399124 on ClinicalTrials.gov